Hoth Therapeutics HOTH 深 沪
等待开盘 03-26 09:30:00 美东时间
0.8987
+0.012
+1.40%
华盛通- 最 高0.9179
- 今 开0.8998
- 成交量 12.16万股
- 最 低 0.885
- 昨 收 0.8863
- 总市值 1394.27万
- 52周最高 2.115
- 市盈率 静 --
- 换手率 0.78%
- 52周最低 0.6554
- 委 比 -63.33%
- 总股本 1551.43万
- 历史最高 347.00
- 量 比 0.36
- 振 幅 3.71%
- 历史最低 0.58
- 每 手 1
- 风险率 0.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BUZZ-U.S. STOCKS ON THE MOVE-DexCom, Ocugen, Estee Lauder
BUZZ-U.S. STOCKS ON THE MOVE-DexCom, Ocugen, Estee Lauder Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 24 (Reuters) - U.S. stock index futures pointed to a lower open on
03-24 21:10
Hoth Therapeutics Reports Data For HT-001; No Serious Adverse Events
PK studies of topical HT-001 reveal limited systemic absorption and ~99% reduced systemic levels as compared to FDA approved oral formulations.
03-24 20:15
Hoth Therapeutics reports HT-001 trial data showing 77% higher systemic exposure and no serious adverse events
Hoth Therapeutics reports HT-001 trial data showing 77% higher systemic exposure and no serious adverse events Hoth reported pharmacokinetic, safety, and clinical activity results from a study of topical HT-001 in cancer patients with EGFR therapy-associated skin toxicities, and the results were pre
03-24 20:13
BUZZ-U.S. STOCKS ON THE MOVE-SSR Mining, Bath & Body Works, CoreWeave
BUZZ-U.S. STOCKS ON THE MOVE-SSR Mining, Bath & Body Works, CoreWeave Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures edged higher on Wednesday as investors
03-04 22:10
EXCLUSIVE: Hoth Therapeutics Integrates OpenAI API To Support Drug Development For Aggressive Cancers
Hoth Therapeutics uses OpenAI API to advance HT-KIT rare cancer therapy after strong preclinical results and tumor reduction.
03-04 21:01
Hoth Therapeutics Announces Expansion Of CLEER-001 Phase 2a Clinical Trial With Addition Of Regis Clinical Research As New Enrolling Site
CLEER-001 Phase 2a Expansion Signals Growing Momentum Behind First-in-Class Therapy for Cancer Patients With No Current FDA-Approved Treatment OptionNEW YORK, Feb. 24, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc.
02-25 05:21
BUZZ-U.S. STOCKS ON THE MOVE-Zimmer Biomet, Datadog, Ecolab
BUZZ-U.S. STOCKS ON THE MOVE-Zimmer Biomet, Datadog, Ecolab Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the Nasdaq edged lower on Tuesday, bogged down by decline
02-10 23:41
BUZZ-Hoth Therapeutics rises as early obesity‑drug data in mice shows promise
BUZZ-Hoth Therapeutics rises as early obesity‑drug data in mice shows promise ** Shares of Hoth Therapeutics HOTH.O rise 3.9% to $0.89 premarket ** Co says its experimental obesity drug HT‑VA GDNF helped mice gain less weight and stabilize weight compared with semaglutide ** Co says the drug also i
02-10 22:27
Hoth Therapeutics Reports GDNF Outperforms Semaglutide in Preclinical Obesity Study
Hoth Therapeutics Reports GDNF Outperforms Semaglutide in Preclinical Obesity Study Hoth Therapeutics Inc. announced preclinical results from a VA-backed study evaluating glial cell-derived neurotrophic factor (GDNF) as a potential treatment for obesity and metabolic-associated steatotic liver disea
02-10 21:31
Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets
NEW YORK, Feb. 5, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for cancer patients with s...
02-05 21:03
